Cancer Journey


VIDEOS

ARTICLES

Question & Answer Session on Immunotherapies for Lung Cancer

Here's the question and answer session that followed the presentations by Drs. Ramaswamy Govindan and Julie Brahmer on the topic of immunotherapies...

The PARAMOUNT Trial Shows a Survival Benefit: Putting Continuation Maintenance Therapy into Context

Last year, the PARAMOUNT trial was one of the highlight presentations in lung cancer from ASCO 2011, an important landmark study of continuation...

Heat Shock Protein Inhibition Provides Another Encouraging Signal for Some Lung Adenocarcinoma Patients with a Worse Prognosis

Historically, lung cancer patients with a KRAS mutation, which is the molecular marker that is actually most common in patients with NSCLC (about 20...

Webinar July 19th: Novel Radiation Techniques in Management of Lung Cancer

On July 19th, we'll run our next webinar program, featuring GRACE Vice President Dr. Vivek Mehta, who is a radiation oncologist and Director of the...

Re-Treatment After Discontinuing an EGFR Tyrosine Kinase Inhibitor: Could this be Better than Retreating Beyond Progression?

In my last post, I described the concept of treating with a targeted therapy like an EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor at the time...

ONLINE COMMUNITY

RECENT POSTS

Stage IIIb ALK NSCLC first line treatment
Is adding durvalumab a game changer?
Last Comment by Jim C GRACE Co… on Nov 1, 2018 5:55 am
Stage IIIb ALK NSCLC first line treatment
FDA approves durvalumab after chemo/rads for unresectable st III
Last Comment by Jim C GRACE Co… on Nov 1, 2018 5:55 am
Stage IIIb ALK NSCLC first line treatment
Is adding durvalumab a game changer?
Last Comment by Jim C GRACE Co… on Nov 1, 2018 5:55 am
Keytruda for Adenocarcinoma (NSCLC), first PET-CT result
Thank you so much Janine. 
Last Comment by semone12 on Oct 24, 2018 1:19 pm
Keytruda for Adenocarcinoma (NSCLC), first PET-CT result
semone12, As is described in
Last Comment by semone12 on Oct 24, 2018 1:19 pm

Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC

Article

Dr. Sarah Goldberg notes that while maintenance therapy after first line treatment of advanced NSCLC is always worthy of a discussion, many patients need and benefit from a break from treatment to recover before pursuing additional therapy.

[powerpress]

Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?

Article

Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.

[powerpress]

Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)

Article

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.

[powerpress]

Subscribe to Lung Cancer